Literature DB >> 11781307

Contribution of estrogen receptor alpha to oncogenic K-Ras-mediated NIH3T3 cell transformation and its implication for escape from senescence by modulating the p53 pathway.

Kiyoko Kato1, Shinji Horiuchi, Akira Takahashi, Yousuke Ueoka, Takahiro Arima, Takao Matsuda, Hidenori Kato, Jun-ichi Nishida Ji, Yusaku Nakabeppu, Norio Wake.   

Abstract

We previously reported that enhanced transcriptional activation of estrogen receptor alpha (ERalpha) contributed to [(12)Val]K-Ras-mediated NIH3T3 cell transformation. Functional inactivation of ERalpha by a dominant negative mutant of ERalpha (DNER) in the presence of activated K-Ras 4B mutant arrested the cell cycle at G(0)/G(1), subsequently provoking replicative cell senescence, finally abrogating tumorigenic potential. p53-dependent up-regulation of p21 was implicated in this cell senescence induction. Alterations in the MDM2 protein in response to DNER accounted for this p21-mediated cell senescence induction. An oncogenic K-Ras 4B mutant significantly increased MDM2 proteins coprecipitated with p53, and suppressed p53 transcriptional activity. In turn, DNER exerted its function to decrease MDM2 proteins coprecipitated with p53, followed by the stimulation of p53 activity in the presence of the oncogenic K-Ras 4B mutant. In addition, overexpression of wild type ERalpha in NIH3T3 cells resulted in the significant increase in the MDM2 protein level and the resultant suppression of p53 transcriptional activity. Finally, we demonstrated that c-Jun expression overcame the suppression and resultant enhancement of p21 protein level in response to DNER. The data imply that the ERalpha-AP1 pathway activated by oncogenic K-Ras 4B mutant contributes to the NIH3T3 cells' transformation by modulating p53 transcriptional activity through MDM2.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11781307     DOI: 10.1074/jbc.M107391200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Common variant on MDM2 contributes to endometrial cancer susceptibility: evidence based on 7 studies.

Authors:  Yan Zhao; Xiaoer Yang; Xiaojiao Hao; Xiaolin Pan; Bo Zhao; Jingwen Ma; Jian Fang; Minghong Zhao
Journal:  Tumour Biol       Date:  2014-05-03

Review 2.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

Review 3.  Sexual dimorphism in cancer.

Authors:  Andrea Clocchiatti; Elisa Cora; Yosra Zhang; G Paolo Dotto
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

4.  Multivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostates.

Authors:  André Fujita; Luciana Rodrigues Gomes; João Ricardo Sato; Rui Yamaguchi; Carlos Eduardo Thomaz; Mari Cleide Sogayar; Satoru Miyano
Journal:  BMC Syst Biol       Date:  2008-12-05

5.  SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers.

Authors:  Kanako Okamoto; Ryosuke Tsunematsu; Tomoko Tahira; Kenzo Sonoda; Kazuo Asanoma; Hiroshi Yagi; Tomoko Yoneda; Kenshi Hayashi; Norio Wake; Kiyoko Kato
Journal:  BMC Med Genet       Date:  2015-08-21       Impact factor: 2.103

6.  Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.

Authors:  Tomoko Yoneda; Ayumi Kuboyama; Kiyoko Kato; Tatsuhiro Ohgami; Kanako Okamoto; Toshiaki Saito; Norio Wake
Journal:  Oncol Rep       Date:  2013-04-29       Impact factor: 3.906

7.  Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.

Authors:  Elisa Baldelli; Guido Bellezza; Eric B Haura; Lucio Crinó; W Douglas Cress; Jianghong Deng; Vienna Ludovini; Angelo Sidoni; Matthew B Schabath; Francesco Puma; Jacopo Vannucci; Annamaria Siggillino; Lance A Liotta; Emanuel F Petricoin; Mariaelena Pierobon
Journal:  Oncotarget       Date:  2015-10-20

8.  Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.

Authors:  Wendy M Swetzig; Jianmin Wang; Gokul M Das
Journal:  Oncotarget       Date:  2016-03-29

9.  Oestrogen receptor-alpha contributes to the regulation of the hedgehog signalling pathway in ERalpha-positive gastric cancer.

Authors:  C Kameda; M Nakamura; H Tanaka; A Yamasaki; M Kubo; M Tanaka; H Onishi; M Katano
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

10.  KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients.

Authors:  Carlos Gil Ferreira; Veronica Aran; Ilana Zalcberg-Renault; Ana Paula Victorino; Jonas H Salem; Martin H Bonamino; Fernando M Vieira; Mariano Zalis
Journal:  BMC Gastroenterol       Date:  2014-04-10       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.